



showing a high-grade dysplastic nevus with nodular melanoma. The histopathological features of the excised specimen were as follows: Breslow 1.41 mm, Clark 3, with a mitotic index over 2 and the presence of microsatellites, classified as pathohistological local stage T2b. The immunohistochemical analysis revealed positive staining for Melanin A+, S100+, and HMB-45. No lympho-vascular or perineural invasions were observed.

One month after the first procedure the excision site was additionally widely excised to a 10 mm margin, followed by skin defect reconstruction with a rotation cutaneous flap (Fig. 1). During the postoperative recovery, no complications were observed. The subsequent follow-up examinations every three months showed no signs of recurrence or presence of local or remote metastases, until the time of writing.

## DISCUSSION

The cutaneous penile shaft melanoma comprises 9% of all penile cases.<sup>2</sup> To the best of our knowledge, this report represents one of the first cases in the Balkan region<sup>7</sup> and the first verified and reported case of penile melanoma in Serbia.

In addition to genetic and constitutional characteristics, which are well-known etiological factors, its development is highly correlated with exposure to UV radiation, particularly intermittent sun exposure,<sup>8</sup> which makes the penile location less common. It usually presents as a painless, pigmented lesion that gradually grows larger and, at the advanced stages, ulcerates with the development of local inguinal lymphadenopathy.<sup>3,4</sup> A poor prognosis is associated with delayed diagnosis and the aggressiveness of the tumor,<sup>3,4</sup> with the presence of ulceration, high Breslow, mitotic and Clark indices, irregular growth pattern, presence of satellite



**Figure 1** – Clinical presentation of the patient: (A) Initial clinical examination; (B) Initial surgical treatment; (C) Additional surgical excision (second surgical treatment); (D) Final result

nodules, lymphovascular invasion, tumor thickness greater than 3.5 mm, diameter greater than 15 mm, and regression pattern being the most important poor prognostic factors.<sup>9</sup>

Due to its rarity, no specific guidelines have been recommended so far for treating penile melanoma. Guidelines for treating penile malignancies in general do not differ depending on the type of cancer but depend on its invasiveness and stage. Surgical treatment of penile melanoma varies depending on the stage of the lesion.<sup>10</sup> Melanomas *in situ* and melanomas that have a Breslow index under 0.75 mm are widely excised. In larger lesions, partial or total penectomy remains the standard of surgical treatment. Sentinel lymph node biopsy followed by inguinal lymphadenectomy is usually recommended if there is micro-metastatic disease or inguinal lymphadenectomy,<sup>11</sup> neither of which was observed in our case. In the case of metastasis of the inguinal lymphatic nodes, radical lymphadenectomy does not improve the chances of survival.<sup>10</sup>

Early diagnosis led to positive outcomes in the presented case during the two-year follow-up period after the organ-preserving surgical treatment and no recurrent disease or palpable lymph nodes were detected.

Penile melanoma has a poor prognosis due to late diagnosis and the presence of negative prognostic factors. Median survival time is 1.7 years for disease with inguinal lymphadenopathy or remote metastasis at the time of diagnosis. For localized disease without a palpable inguinal lymphatic node at first examination, median survival time is 2.8 years from the moment of diagnosis.<sup>4</sup> Therefore, early detection is crucial for improving survival rates, but the hidden location often delays diagnosis. Also, diagnosing this condition in its early stages may be impacted by the patient's willingness to attend an appointment (as a result of possible benign initial aspects of the disease and social/cultural aspects) and physicians' awareness of genital diseases, both of which may lead to delay in diagnosis and compromising outcomes.<sup>12,13</sup> Therefore, efforts should be made in order to remove any hurdles from both the patients' and physicians' side in order to ensure detection of such a malignancy in its early stages.

## CONCLUSION

The unusual location makes penile melanoma a clinical challenge. However, despite the rarity of the location, it is important to conduct a thorough systematic clinical examination to prevent misleading diagnosis. Proper diagnosis in early stages and evidence-based choice of treatment are

extremely important for successful management. Since surgical excision remains the standard of care, it is important to conduct organ-preserving surgery for penile melanoma whenever possible in order to prevent a decrease in these patients' quality of life.

## ACKNOWLEDGEMENTS

The authors express appreciation and gratitude to Nina Jovanovic, Dragan Gacic, Dejan Opric, and Dejan Nikolic for their valuable and constructive suggestions, enthusiastic encouragement, and useful critiques during the planning and development of this case report, as well as for their advice and assistance in keeping the progress of the manuscript preparation on schedule.

## AUTHOR CONTRIBUTIONS

JG, AL, MLB, JB, MN: Conception and design of the work, data acquisition, analysis and interpretation, drafting and critical review of the manuscript.

SN: Data acquisition, analysis and interpretation, drafting and critical review of the manuscript.

All authors approved the final version to be published.

## PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in October 2024.

## DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients' data publication.

## PATIENT CONSENT

Obtained.

## COMPETING INTERESTS

The authors have declared that no competing interests exist.

## FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## REFERENCES

1. Brady KL, Mercurio MG, Brown MD. Malignant tumors of the penis. *Dermatol Surg.* 2013;39:527-47.
2. Leitão LF, Orellana FM, Simões JP, Lellis RF, Maia M, Fernandes RC, et al. Penile melanoma. *Braz J Oncol.* 2021;17:e-20200040.
3. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettawayet CA. Melanoma of the penis, scrotum, and male urethra: a 40-year single institution experience. *J Urol.* 2005;173:1958-65.
4. Jabiles AG, Del Mar EY, Perez GA, Vera FQ, Montoya LM, Dezaet CM.

Penile melanoma: a 20-Year analysis of six patients at the National Cancer Institute of Peru, Lima. *Ecancermedicalscience*. 2017;11:731.

5. Bechara GR, Schwindt AB, Ornellas AA, da Silva DE, Lott FM, de Camoset FS. Penile primary melanoma: analysis of 6 patients treated at Brazilian National Cancer Institute in the last eight years. *Int Braz J Urol*. 2013;39:823-31.
6. Kouyaté M, D'horpock AF, Aman NA, Traore ZC, Coulibaly ZI, Kouï BS, et al. Melanoma of the penis: a case diagnosed at the anatomic pathology laboratory of the treichville teaching hospital. *Hum Pathol: Case Reports*. 2018;11:32-3.
7. Tchernev G, Temelkova I. Preputial melanoma. *Wien Med Wochenschr*. 2021;171:41-2.
8. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med*. 2005;353:2135-47.
9. van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BB, de Wilt JH, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. *Urology*. 2007;70:143-7.
10. Andrei R, Cioplea M, Mageriu V, Chuaibi A, Cauni V, Zurac S, et al. Primary penile melanoma. *Rom J Intern Med*. 2014;52:121-5.
11. Muneer A, Bandini M, Compérat E, De Meerleer G, Fizazi K, Gietema J, et al. Penile cancer: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. *ESMO Open*. 2024;9:103481.
12. Skeppner E, Andersson SO, Johansson JE, Windahl T. Initial symptoms and delay in patients with penile carcinoma. *Scand J Urol Nephrol*. 2012;46:319-25.
13. Teichman JM, Mannas M, Elston DM. Noninfectious penile lesions. *Am Fam Physician*. 2018;97:102-10.